# Alpha-adrenergic blockers and central alpha-2 agonists

Drug · id `cardio:alpha-adrenergic-blockers-and-central-alpha-2-agonists` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Alpha blockers; Adrenergic alpha-antagonists; Central alpha-2 agonists

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

Two groups of medicines that lower blood pressure through the alpha-adrenergic system. The alpha blockers block alpha-adrenergic receptors; MeSH says they are used in high blood pressure, vasospasm, peripheral vascular disease, shock and pheochromocytoma. The central alpha-2 agonists act through the central nervous system. The US labels read for one of each list high blood pressure, and the alpha blocker label lists prostate enlargement as well.

## Technical summary

Class page for two related groups, written as one because the plan combined them. MeSH descriptors D000317 (Adrenergic alpha-Antagonists, last updated 2018-06-14) and D058647 (Adrenergic alpha-2 Receptor Agonists, last updated 2011-01-01) are both broad matches, because neither alone is the whole page. Two US labels were read. CARDURA (doxazosin tablets, application NDA019668, effective 2023-10-15 in openFDA) calls the medicine an alpha 1 adrenergic antagonist and lists benign prostatic hyperplasia and hypertension. Catapres-TTS (clonidine transdermal system, application NDA018891, effective 2026-01-06 in openFDA) is indicated for hypertension, describes clonidine as a centrally acting agent, and the openFDA record gives the established pharmacologic class Central alpha-2 Adrenergic Agonist. The second MeSH scope note is only one sentence. This page gives no dose, no trial result and no guideline statement; no warning in either label was recorded. Medicines of the groups that have their own pages are filed under it.

## Claims, with the population each applies to

## Context: People with hypertension, and men with benign prostatic hyperplasia for the alpha blocker, as described in two US labels

Recipient: Recipient not specified; Population: Patients described in the indications sections of the two labels: patients with hypertension, and for the alpha blocker label also patients with the signs and symptoms of benign prostatic hyperplasia.; Care setting: Prescription medicine, as described in the US labels; Geography: United States (US drug labels); Life stage: Not stated in the passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### Two US labels were read. The label of CARDURA (doxazosin tablets, Viatris Specialty LLC, application NDA019668; the version dated 2023-10-15 in openFDA) calls the medicine an alpha 1 adrenergic antagonist and lists the signs and symptoms of benign prostatic hyperplasia and the treatment of hypertension. The label of Catapres-TTS (clonidine transdermal system, Technomed Inc., application NDA018891; the version dated 2026-01-06 in openFDA) says it is indicated in the treatment of hypertension and describes clonidine as a centrally acting agent; openFDA's record gives the established pharmacologic class Central alpha-2 Adrenergic Agonist. MeSH says alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock and pheochromocytoma.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications sections of the two labels: patients with hypertension, and for the alpha blocker label also patients with the signs and symptoms of benign prostatic hyperplasia.; Care setting: Prescription medicine, as described in the US labels; Geography: United States (US drug labels); Life stage: Not stated in the passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what two US labels say. It is not a finding about how well either medicine works, and no trial result is recorded for it in this atlas. The prostate indication belongs to the alpha blocker label only. The pharmacologic class name for the second medicine comes from openFDA's record of its label. The second label is for a skin patch; an oral form of the same medicine was not read. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for CARDURA (doxazosin tablets), Viatris Specialty LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 5e1f5e49-2da1-43ab-9795-228a8bcc5a82 (manufacturer Viatris Specialty LLC, application NDA019668), returned on 2026-11-09. The label text is dated 2023-10-15 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%225e1f5e49-2da1-43ab-9795-228a8bcc5a82%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-09T13:17:42Z. Source state: Current. Version fingerprint: 2493e9d5346ff8f7d721f288aecee512a7d67a1a821ff0bc5d51ecc0e171f615.
     How it applies: Alpha 1 adrenergic antagonist; BPH and hypertension.
  2. Background: openFDA drug label record for CARDURA (doxazosin tablets), Viatris Specialty LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 5e1f5e49-2da1-43ab-9795-228a8bcc5a82 (manufacturer Viatris Specialty LLC, application NDA019668), returned on 2026-11-09. The label text is dated 2023-10-15 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%225e1f5e49-2da1-43ab-9795-228a8bcc5a82%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:17:42Z. Source state: Current. Version fingerprint: 2493e9d5346ff8f7d721f288aecee512a7d67a1a821ff0bc5d51ecc0e171f615.
     How it applies: Effective date of the label text read, 20231015.
  3. Supports: openFDA drug label record for Catapres-TTS (clonidine transdermal system), Technomed Inc. label: indications and class description (Regulator, edition The openFDA drug label record for set id 39e1d35e-533c-4647-8649-8168a6e92dfa (manufacturer Technomed Inc., application NDA018891), returned on 2026-11-09. The label text is dated 2026-01-06 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2239e1d35e-533c-4647-8649-8168a6e92dfa%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], INDICATIONS AND USAGE. Retrieved 2026-11-09T13:17:44Z. Source state: Current. Version fingerprint: 25b034f47f06bcd1ee51201e6a4304164ccc881c2f64f9b3b48af68ba3e7be66.
     How it applies: Hypertension use of the clonidine patch.
  4. Supports: openFDA drug label record for Catapres-TTS (clonidine transdermal system), Technomed Inc. label: indications and class description (Regulator, edition The openFDA drug label record for set id 39e1d35e-533c-4647-8649-8168a6e92dfa (manufacturer Technomed Inc., application NDA018891), returned on 2026-11-09. The label text is dated 2026-01-06 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2239e1d35e-533c-4647-8649-8168a6e92dfa%22&limit=1>
     Locator: results\[0\].openfda.pharm\_class\_epc\[0\]. Retrieved 2026-11-09T13:17:44Z. Source state: Current. Version fingerprint: 25b034f47f06bcd1ee51201e6a4304164ccc881c2f64f9b3b48af68ba3e7be66.
     How it applies: Established pharmacologic class in openFDA: Central alpha-2 Adrenergic Agonist.
  5. Background: openFDA drug label record for Catapres-TTS (clonidine transdermal system), Technomed Inc. label: indications and class description (Regulator, edition The openFDA drug label record for set id 39e1d35e-533c-4647-8649-8168a6e92dfa (manufacturer Technomed Inc., application NDA018891), returned on 2026-11-09. The label text is dated 2026-01-06 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2239e1d35e-533c-4647-8649-8168a6e92dfa%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:17:44Z. Source state: Current. Version fingerprint: 25b034f47f06bcd1ee51201e6a4304164ccc881c2f64f9b3b48af68ba3e7be66.
     How it applies: Effective date of the label text read, 20260106.
  6. Supports: MeSH scope note for descriptor D000317 (Adrenergic alpha-Antagonists) (Dataset, edition MeSH linked-data record of the preferred concept M0000493 of descriptor D000317, fetched 2026-11-09. The scope note is on this concept record, not on the descriptor record.) <https://id.nlm.nih.gov/mesh/M0000493>
     Locator: scopeNote.@value. Retrieved 2026-11-09T13:15:47Z. Source state: Current. Version fingerprint: 5e459df894b106c7bfd5f9d8996b03f3c29594b42073a810102193c01b8cfc4c.
     How it applies: MeSH scope note: uses of alpha-antagonists.

## Connected pages

- Two US labels list treating high blood pressure as an indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-alpha-labels-indications` and its context]
- Blood pressure lowering medicine, the care strategy: Blood pressure lowering medicine (`cardio:bp-lowering-medicine`)
- Files under this front: Medicines (`cardio:front-medicines`)
- Has subtype: Clonidine (`cardio:clonidine`)

## Provenance

Content hash: 9909b795268356a22ed4e507ad06a749666b660a7d7468dc8f55787bb8affa9a
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
